Inhibiting the precipitation of poorly water-soluble drugs from labrasol formulations

Pharmaceutical Technology

Volumn 35, Issue 6, 2011, Pages 50-55

  Dai, Wei Guo ^a   Dong, Liang C ^b   Creasey, Abla A ^c  

^a Johnson and Johnson Pharmaceutical Research and Development   (United States)

^b ADDS Pharmaceuticals   (United States)

^c JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLURONIC F-127; POLYETHYLENE GLYCOL 400; POORLY WATER-SOLUBLE DRUGS; POTENT INHIBITOR; PRECIPITATION INHIBITORS;

GLYCOLS; IONIC LIQUIDS;

POLYETHYLENE GLYCOLS;

LABRASOL; LIPID; POLOXAMER; SURFACTANT;

ARTICLE; DILUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; EMULSION; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; MICROEMULSION; PRECIPITATION;

EID: 80051888080     PISSN: 15432521     EISSN: 21507376     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. A. Désiré et al., Pharm. Technol. 35 (1), 56-65 (2011).
2. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147-152 (1999).
3. G. Tomer, F. Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1-2), 237-248 (2001).
4. G. Tomer, F. Podczeck, and J.M. Newton, Int. J. Pharm. 231 (1), 248-257 (2002).
5. J.J. Sousa et al., Int. J. Pharm. 232 (1-2), 91-106 (2002).
6. J. Chatchawalsaisin, F. Podczeck, and J.M. Newton, Eur J Pharm Sci. 24 (1), 35-48 (2005).
7. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643-659 (2005).
8. F.O. Costa, A.A.C.C. Pais, and J.J.S., Int. J. Pharm. 270 (1-2), 9-19 (2004).
9. G.A. Hileman et al., Int. J. Pharm. 100 (1-3), 71-79 (1993).
10. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219-222 (1994).
11. L. Alvarez et al., Eur. J. Pharm. Biopharm. 55 (3), 291-295 (2003).
12. R. Gandhi et al., Pharm. Technol. 29 (2). 68-86 (2005).
13. L. Rahman et al., STP Pharm. Sci. 1 (5), 294-299 (1991).
14. E. Nürnberg, and J. Wunderlich, Pharm. Technol. Eur. 11 (3), 30-34 (1999).
15. S. Galland, T. Ruiz, and M. Delalonde, Int. J. Pharm. 337 (1-2), 239-245 (2007).
16. S. Galland, T. Ruiz, and M. Delalonde, Powder Technol. 190 (1-2), 48-52 (2009).
17. J.F. Pinto and C.N. Abreu, Drug. Dev. Ind. Pharm. 32 (9), 1067-1078 (2006).
18. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1-3), 197-204 (1993).
19. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1-3), 205-216 (1993).
20. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1-3), 217-223 (1993).
21. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2), 205-214 (1997).
22. V.R. Sinha et al., AAPSPharmSciTech, 8 (1), E1-E5 (2007).
23. S. Galland et al., Powder Technol. 157 (1-3), 156-162 (2005).
24. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53-60 (1995).
25. E.I. Hamedelniel, J. Bajdik, and K. Pintye-Hódi, Chemical Engineering and Processing: Process Intensification 49 (1), 120-124 (2010).
26. A. Häring, K. Krejcova, and M. Rabiskova, Farm. Vestn. 54 (special issue), 437-438 (2003).
27. L. Baert et al., Int. J. Pharm. 86 (2-3), 187-192 (1992).
28. L. Baert et al., Int. J. Pharm. 99 (1), 7-12. (1993).
29. C. Schmidt, H. Lindner, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 44 (2), 169-176 (1997).
30. K. Thoma and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 401-411 (1998).
31. K. Thoma, and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 413-422 (1998).
32. D. Sonaglio, B. Bataille, and M. Jacob, Pharm. Acta Helv. 72 (2), 69-74 (1997).
33. C. Schmidt, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 45 (2), 173-179 (1998).
34. J.M. Newton, S.R. Chapman, and R.C. Rowe, Int. J. Pharm. 120 (1), 101-109 (1995).
35. D. Sonaglio et al., Pharmazie 52 (2), 129-134 (1997).
36. P. Costa and J.M. Sousa Lobo, Eur. J. Pharm. Sci. 13 (2), 123-133 (2001).
37. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65-71 (1995).
38. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1-3), 49-58 (1993).
39. A.B. Bashaiwoldu, F. Podczeck and J.M. Newton, Eur. J. Pharm. Sci. 21 (2-3), 119-129 (2004).
40. B. Song, S.L. Rough, and D.I. Wilson, Int. J. Pharm. 332 (1-2), 38-44 (2007).
41. J.P. Perez and M. Rabiskova, Int. J. Pharm. 242 (1-2), 349-351 (2002).
42. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159-169 (1996).
43. J. Berggren and G. Alderborn, Int. J. Pharm. 219 (1-2), 113-126 (2001).
44. P. Kleinebudde, Int. J. Pharm. 109 (3), 209-219 (1994).
45. P. Kleinebudde, Int. J. Pharm. 109 (3), 221-227 (1994).
46. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334-337 (1990).
47. K. Ligarski et al., STP Pharma Sci. 1 (4), 256-261 (1991).
48. B. Bataille et al., Drug Dev. Ind. Pharm. 19 (6), 653-671 (1993).
49. K. Umprayn, P. Chitropas, and S. Amarekajorn, Drug Dev. Ind. Pharm. 25 (1), 45-61 (1999).